EFFICACY OF DIHYDROQUERCETIN NANOEMULSION IN TYLOXAPOL-INDUCED HYPERLIPIDEMIC MICE

Tóm tắt

Dihydroquercetin (DHQ), also called as taxifolin, has been reported to have many beneficial properties for human health. However, its low solubility and bioavailability are major obstacles for the biomedical application of the flavonoid. This study aims to evaluate the effects of dihydroquercetin (DHQ) and dihydroquercetin loaded self-nano-emulsifying drug delivery systems (NanoDHQ) containing 8% DHQ on lipid profiles in tyloxapol-induced hyperlipidemic mice. Swiss albino mice were daily treated with DHQ (24 and 48 mg/kg, p.o) or NanoDHQ (37.5, 75 and 150 mg/kg) or fenofibrate (100 mg/kg, p.o), a reference drug, two week before tyloxapol injection (Triton WR 1339, 250 mg/kg, i.v). After 16-hour administration of tyloxapol, blood was collected and the levels of serum total cholesterol (TC), triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), non-high-density lipoprotein-cholesterol (non-HDL-C), and low-density lipoprotein-cholesterol (LDL-C) were measured. Our results showed that the levels of TC, TG, LDL-C, non-HDL-C in the model group were significantly increased, while the HDL-C level of the animals were markedly decreased in comparing with the control group. The treatment of DHQ at the dose of 48 mg/kg significantly decreased TG level but not altered the other lipid indexes as compared to the model group. Interestingly, the administration of NanoDHQ (75 and 150 mg/kg) significantly and dose-dependently attenuated the elevation of TC and TG level in the tyloxapol-treated mice. Moreover, the NanoDHQ treatment ameliorated the reduction of HDL-C level and the elevation of non-HDL-C level in the Tyloxapol-treated animals. NanoDHQ treatment had no significant effect on LDL-C levels of the animals. In conclusion, the present study demonstrated that the administration of NanoDHQ enhanced the efficacy of DHQ on hypolipidemic activity in tyloxapol-induced hyperlipidemic mice. NanoDHQ treatment may be useful for treatment of hyperlipidemia.